Business
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
(TheNewswire)   Toronto, Ontario – TheNewswire - May 22, 2026 – Helix ...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options\n(TheNewswire)\n\n\n\n \n\n\nToronto, Ontario – TheNewswire\n- May 22, 2026 – Helix BioPharma Corp. (TSX:\n“HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)\n(“Helix” or the “Company”), a clinical-stage oncology\ncompany shaping a near future where today’s hard-to-treat cancers\nare vincible, today announced that the board of directors has granted\n1,297,000 incentive stock options to directors, officers, employees\nand consultants of the Company pursuant to its equity compensation\nplan.\n\n\nEach stock option is exercisable to acquire one common\nshare of the Company at an exercise price of $1.63 per share for a\nperiod of five years from the date of grant. The options are subject\nto various vesting provisions in accordance with the terms of the\nCompany’s equity compensation plan and the applicable option\nagreements.\n\n\n \n\n\nThe Company also announces the cancellation of an\naggregate of 2,200,000 incentive stock options (the “Cancelled Options”)\npreviously granted pursuant to the Company’s equity compensation\nplan on July 19, 2024. The Cancelled Options were held by a director\nof the Company, had an exercise price of $1.10 per common share and\nwere set to expire on July 19, 2029. The director did not receive any\nstock options pursuant to the current grant.\n\n\n \n\n\nAbout Helix BioPharma\n\n\nHelix BioPharma is an oncology company that innovates\nfrom strength to bring near-term solutions for today’s\nhardest-to-treat cancers. The Company’s pipeline is led by Tumor\nDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate\ndesigned to prime CEACAM6-expressing tumors for increased sensitivity\nto therapy and augment the effectiveness of today’s front-running\nanti-cancer treatments. L-DOS47 has completed Phase Ib studies in\nnon-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting\nfoundation with Helix’s next-generation bi-specific antibody-drug\nconjugates (ADCs), currently in discovery. The Company also advances\ntwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint\nmodulator aimed at achieving durable remission in post-transplant\nleukem...